Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study.

ABSTRACT:

Objectives

To evaluate the added benefit and revenues of oncology drugs, explore their association, and investigate potential discrepancies between added benefit and revenues across different approval pathways of the European Medicines Agency (EMA).

Design

Retrospective cohort study.

Setting

Oncology drugs and their indications approved by the EMA between 1995 and 2020.

Main outcome measures

Added benefit was evaluated using ratings published by seven organisations: health technology assessment agencies from the United States, France, Germany, and Italy, two medical oncology societies, and a drug bulletin. All retrieved ratings were recategorised using a four point ranking scale to indicate negative or non-quantifiable, minor, substantial, or major added benefi

SUBMITTER: Brinkhuis F 

PROVIDER: S-EPMC10899806 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature